Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02

Journal of Clinical Oncology

Volumn 31, Issue 14, 2013, Pages 1732-1739

  Park, Yeon Hee ^a   Jung, Kyung Hae ^b   Im, Seock Ah ^c   Sohn, Joo Hyuk ^d   Ro, Jungsil ^f   Ahn, Jin Hee ^b   Kim, Sung Bae ^b   Nam, Byung Ho ^f   Oh, Do Youn ^c   Han, Sae Won ^c   Lee, Soohyeon ^d   Park, In Hae ^f   Lee, Keun Seok ^f   Kim, Jee Hyun ^g   Kang, Seok Yun ^h   Lee, Moon Hee ⁱ   Park, Hee Sook ^e   Ahn, Jin Seok ^a   Im, Young Hyuck ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e SoonChunHyang University Hospital   (South Korea)

^f National Cancer Center   (South Korea)

^g Seoul National University Bundang Hospital   (South Korea)

^h Ajou University School of Medicine   (South Korea)

ⁱ Inha University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEMCITABINE; GOSERELIN; LETROZOLE; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PLEURA METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING; WATCHFUL WAITING; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; SOUTH KOREA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; TREATMENT OUTCOME; WATCHFUL WAITING;

MLCS; MLOWN;

EID: 84879476708     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.2490     Document Type: Article

References (20)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
2. Thun MJ, Jemal A, Ward E: Global cancer incidence and mortality, in DeVita VT Jr: Cancer: Principles and Practice of Oncology (ed 9). Philadelphia, PA, Lippincott Williams & Wilkins, 2011, pp 241-266
3. Ejlertsen B, Pfeiffer P, Pedersen D, et al: Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29A:527-531, 1993
4. Muss HB, Case LD, Richards F 2nd, et al: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer: The Piedmont Oncology Association. N Engl J Med 325:1342-1348, 1991
5. Falkson G, Gelman RS, Pandya KJ, et al: Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 16:1669-1676, 1998
6. Coates A, Gebski V, Bishop JF, et al: Improving the quality of life during chemotherapy for advanced breast cancer: A comparison of intermittent and continuous treatment strategies. N Engl J Med 317:1490-1495, 1987
7. Harris AL, Cantwell BM, Carmichael J, et al: Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 335:186-190, 1990
8. Dixon AR, Jackson L, Chan SY, et al: Continuous chemotherapy in responsive metastatic breast cancer: A role for tumour markers? Br J Cancer 68:181-185, 1993
9. Gregory RK, Powles TJ, Chang JC, et al: A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 33:2194-2197, 1997
10. Nooij MA, de Haes JC, Beex LV, et al: Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: Clinical outcomes and oncologists’ preferences. Eur J Cancer 39:614-621, 2003
11. Gennari A, Amadori D, De Lena M, et al: Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24:3912-3918, 2006
12. Gennari A, Stockler M, Puntoni M, et al: Duration of chemotherapy for metastatic breast cancer: A systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 29:2144-2149, 2011
13. O’Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002
14. Albain KS, Nag SM, Calderillo-Ruiz G, et al: Gemcitabine plus paclitaxel versus paclitaxel mono-therapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26: 3950-3957, 2008
15. Chan S, Romieu G, Huober J, et al: Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 27:1753-1760, 2009
16. Therasse P, Le Cesne A, Van Glabbeke M, et al: RECIST vs. WHO: Prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer 41:1426-1430, 2005
17. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
18. Gennari A, D’Amico M, Corradengo D: Extending the duration of first-line chemotherapy in metastatic breast cancer: A perspective review. Ther Adv Med Oncol 3:229-232, 2011
19. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (ed V. 2.2010). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
20. Alba E, Ruiz-Borrego M, MargelíM, et al: Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEI-CAM 2001-01 study. Breast Cancer Res Treat 122: 169-176, 2010